EU5 Neuromodulation Devices Outlook to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.


“What is covered in the report about the “EU5 Neuromodulation Devices Market”?
GlobalData’s “EU5 Neuromodulation Devices Market Outlook to 2025” report is a comprehensive databook report, covering key market data on the EU5 Neuromodulation Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Deep Brain Stimulators (DBS), Gastric Electric Stimulators (GES), Leads, Peripheral Nerve Stimulators (PNS), Sacral Nerve Stimulators (SNS), Spinal Cord Stimulators (SCS) and Vagus Nerve Stimulators (VNS).

The EU5 Neuromodulation Devices Market report provides key information and data on
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2015 to 2025.
• 2018 company share and distribution share data for Neuromodulation Devices market.
• Global corporate-level profiles of key companies operating within the EU5 Neuromodulation Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

EU5 Neuromodulation Devices is segmented as follows:
• Deep Brain Stimulators (DBS)
• Gastric Electric Stimulators (GES)
• Leads
• Peripheral Nerve Stimulators (PNS)
• Sacral Nerve Stimulators (SNS)
• Spinal Cord Stimulators (SCS)
• Vagus Nerve Stimulators (VNS)

Key Reasons to Purchase
The EU5 Neuromodulation Devices Market report helps you to develop
• Business strategies by identifying the key market segments poised for strong growth in the future.
• Market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Key companies covered in the “EU5 Neuromodulation Devices Market Outlook to 2025” report
• Medtronic plc
• Abbott Laboratories

The GlobalData Differentiation
Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis.
The data and analysis within this report are driven by GlobalData Medical Equipment (GDME) databases. GlobalData Medical Equipment database gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:
• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
• 15,000+ primary interviews, conducted annually to ensure data and report quality
• 3,500+ industry-leading analysis and procedure reports covering growing sectors, market trends, investment opportunities and competitive landscape
• 66.956+ medical equipment company profiles
• 4,300+ company profiles of medical equipment manufacturers in China and India
• 825+ companies’ revenue splits and market shares
• 2,000+ quarterly and annual medical equipment company financials
• 1,100+ medical equipment company SWOTs
• 26,400+ pipeline product profiles
• 52,400+ marketed product profiles
• 44,600+ clinical trials
• 52,400+ trial investigators
• 7,900+ reports on companies with products in development
• 42,000+ deals in the medical equipment industry
For more information or to receive a free demonstration of the service, please visit:

Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.



Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 What Is This Report About? 8

2.2 Neuromodulation Devices Market Segmentation 8

2.3 Definitions of Markets Covered in the Report 9

3 Neuromodulation Devices Market, EU5 10

3.1 Neuromodulation Devices Market, EU5, Revenue ($m), 2015-2025 10

3.2 Neuromodulation Devices Market, EU5, Revenue ($m), 2015-2025 12

3.3 Neuromodulation Devices Market, EU5, Volume (Units), 2015-2025 15

3.4 Neuromodulation Devices Market, EU5, Volume (Units), 2015-2025 17

3.5 Neuromodulation Devices Market, EU5, Company Share by Revenue ($m), 2018 20

4 Neuromodulation Devices Market, France 22

4.1 Neuromodulation Devices Market, France, Revenue ($m), 2015-2025 22

4.2 Neuromodulation Devices Market, France, Volume (Units), 2015-2025 25

4.3 Neuromodulation Devices Market, France, Average Price ($), 2015-2025 28

4.4 Neuromodulation Devices Market, France, Distribution Share by Revenue ($m), 2018 30

4.5 Neuromodulation Devices Market, France, Company Share by Revenue ($m), 2018 31

5 Neuromodulation Devices Market, Germany 33

5.1 Neuromodulation Devices Market, Germany, Revenue ($m), 2015-2025 33

5.2 Neuromodulation Devices Market, Germany, Volume (Units), 2015-2025 36

5.3 Neuromodulation Devices Market, Germany, Average Price ($), 2015-2025 39

5.4 Neuromodulation Devices Market, Germany, Distribution Share by Revenue ($m), 2018 41

5.5 Neuromodulation Devices Market, Germany, Company Share by Revenue ($m), 2018 42

6 Neuromodulation Devices Market, Italy 44

6.1 Neuromodulation Devices Market, Italy, Revenue ($m), 2015-2025 44

6.2 Neuromodulation Devices Market, Italy, Volume (Units), 2015-2025 47

6.3 Neuromodulation Devices Market, Italy, Average Price ($), 2015-2025 50

6.4 Neuromodulation Devices Market, Italy, Distribution Share by Revenue ($m), 2018 52

6.5 Neuromodulation Devices Market, Italy, Company Share by Revenue ($m), 2018 53

7 Neuromodulation Devices Market, Spain 55

7.1 Neuromodulation Devices Market, Spain, Revenue ($m), 2015-2025 55

7.2 Neuromodulation Devices Market, Spain, Volume (Units), 2015-2025 58

7.3 Neuromodulation Devices Market, Spain, Average Price ($), 2015-2025 61

7.4 Neuromodulation Devices Market, Spain, Distribution Share by Revenue ($m), 2018 63

7.5 Neuromodulation Devices Market, Spain, Company Share by Revenue ($m), 2018 64

8 Neuromodulation Devices Market, United Kingdom 66

8.1 Neuromodulation Devices Market, United Kingdom, Revenue ($m), 2015-2025 66

8.2 Neuromodulation Devices Market, United Kingdom, Volume (Units), 2015-2025 69

8.3 Neuromodulation Devices Market, United Kingdom, Average Price ($), 2015-2025 72

8.4 Neuromodulation Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2018 74

8.5 Neuromodulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2018 75

9 Overview of Key Companies in EU5 Neuromodulation Devices Market 77

9.1 Medtronic Plc 77

9.1.1 Company Overview 77

9.2 Abbott Laboratories 77

9.2.1 Company Overview 77

9.3 Boston Scientific Corp 77

9.3.1 Company Overview 77

9.4 LivaNova PLC 77

9.4.1 Company Overview 77

9.5 Nevro Corp 78

9.5.1 Company Overview 78

10 Neuromodulation Devices Market Pipeline Products 79

11 Recent Developments 86

11.1 Corporate Communications 86

11.1.1 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 86

11.1.2 Nov 11, 2019: Dr. Leena Niemistö starts as new Chair of the Board of Nexstim 86

11.1.3 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 87

11.1.4 Oct 15, 2019: Changes in the Nexstim Board 88

11.1.5 Aug 28, 2019: Medtronic announces planned leadership succession 88

11.1.6 Aug 12, 2019: GSK announces leadership changes in the US 89

11.1.7 Jul 29, 2019: Sanofi: Appointment of additional director and whole time director 90

11.1.8 Jul 26, 2019: Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer 90

11.1.9 Jul 25, 2019: Nexstim Plc: Change in members of the board committees 91

11.1.10 Jul 24, 2019: GlaxoSmithKline appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors 91

11.1.11 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 92

11.1.12 Jul 24, 2019: GlaxoSmithKline appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors 92

11.1.13 Jul 05, 2019: Gungor Kara appointed new Chief Digital Officer of Ottobock 93

11.1.14 Jun 24, 2019: Jorg Wahlers appointed new Chief Financial Officer 93

11.1.15 Jun 19, 2019: LivaNova welcomes Stacy Enxing Seng to Board of Directors 94

11.1.16 Jun 07, 2019: Paul Hudson to succeed Olivier Brandicourt as chief executive officer 95

11.1.17 Apr 24, 2019: Nexstim names Professor Paul Fitzgerald to Scientific Advisory Board 95

11.1.18 Apr 10, 2019: Professor Alvaro Pascual-Leone joins Nexstim scientific advisory board 96

11.1.19 Apr 05, 2019: Professor Linda Carpenter joins Nexstim's Scientific Advisory Board 96

11.1.20 Mar 29, 2019: PolarityTE announces Richard Hague, formerly from Sanofi, Genzyme and recently Anika Therapeutics as Chief Operating Officer 97

11.1.21 Mar 28, 2019: GlaxoSmithKline Pharmaceuticals: Change in directorate 97

11.1.22 Mar 18, 2019: LivaNova announces Trui Hebbelinck as Chief Human Resources Officer 98

11.1.23 Mar 14, 2019: Medtronic names Andrea J. Goldsmith as a new director 98

11.1.24 Mar 04, 2019: California Life Sciences Association (CLSA) adds GlaxoSmithKline and Blade Therapeutics to Board 99

11.1.25 Mar 01, 2019: Pius S. Hornstein, PhD, appointed new country chair of Sanofi China 99

11.1.26 Feb 12, 2019: Sanofi names Ameet Nathwani as chief digital officer 100

11.1.27 Feb 06, 2019: Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director 101

11.1.28 Jan 22, 2019: Management Board appoints Philipp Schulte-Noelle as CEO 101

11.1.29 Jan 21, 2019: GlaxoSmithKline announces resignation of Sir Philip Hampton as non-executive chairman 102

11.1.30 Jan 21, 2019: GSK announces succession plan to appoint new Chairman 102

11.2 Financial Announcements 103

11.2.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 103

11.2.2 Oct 31, 2019: Sanofi Q3 well on track 104

11.2.3 Oct 30, 2019: LivaNova reports third quarter 2019 results 107

11.2.4 Aug 20, 2019: Medtronic reports first quarter financial results for 2019 108

11.2.5 Aug 16, 2019: Nexstim half-yearly report 1 January – 30 June 2019 110

11.2.6 Jul 31, 2019: LivaNova reports second quarter 2019 results 111

11.2.7 Jul 29, 2019: Sanofi delivered solid growth in Q2 2019 112

11.2.8 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 120

11.2.9 Jul 24, 2019: GSK delivers sales and earnings growth in Q2 2019 121

11.2.10 Jul 17, 2019: AorTech International: Final results for the year ended 31 March 2019 122

11.2.11 May 23, 2019: Medtronic announces fiscal year and fourth quarter 2019 financial results 124

11.2.12 May 07, 2019: Avanos Medical announces first quarter 2019 results 127

11.2.13 May 06, 2019: Continued profitable growth for Carl Zeiss Meditec 128

11.2.14 May 06, 2019: Carl Zeiss Meditec: First half year 2018/2019 129

11.2.15 May 01, 2019: LivaNova announces first quarter 2019 results 130

11.2.16 May 01, 2019: GSK delivers sales of £7.7 billion +6% AER, +5% CER 131

11.2.17 Apr 12, 2019: Carl Zeiss Meditec reports further growth and defines expectations for fiscal year 2018/19 132

11.2.18 Apr 05, 2019: LivaNova reports preliminary unaudited first quarter 2019 revenue results 132

11.2.19 Feb 27, 2019: LivaNova reports fourth quarter and full-year 2018 results 132

11.2.20 Feb 19, 2019: Medtronic reports third quarter financial results 134

11.2.21 Feb 11, 2019: Continued profitable growth for Carl Zeiss Meditec in the first three months of 2018/19 136

11.2.22 Feb 07, 2019: Sanofi delivers 2018 business EPS growth of

5.1% at CER 137

11.2.23 Feb 06, 2019: GSK delivers sales, earnings and cash flow growth in 2018 145

11.2.24 Jan 14, 2019: Carl Zeiss Meditec achieves strong revenue and EBIT growth in first three months 2018/19 146

11.3 Government and Public Interest 146

11.3.1 Jan 09, 2019: Medtronic Foundation Recognizes 12 Bakken Invitation Honorees for Driving Positive Change in Healthcare 146

11.4 Legal And Regulatory 147

11.4.1 Sep 13, 2019: Vectura provides update on GSK Litigation 147

11.4.2 Jul 16, 2019: Swiss agree to extradite Chinese researcher in US corporate espionage case 148

11.4.3 May 04, 2019: Vectura wins US GSK Patent Litigation and awarded $89.7Million in damages by Trial Jury 148

11.4.4 Feb 15, 2019: BRAVO BIDCO: Update on the proposed acquisition of BTG 149

11.4.5 Jan 22, 2019: Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences 149

11.5 Other Significant Developments 149

11.5.1 Oct 22, 2019: EPFL spin-off GTX medical moves into the US market 149

11.5.2 Sep 10, 2019: Kazan Federal University and Mayo Clinic implement unique rehabilitation technology to treat spinal cord injuries 150

11.5.3 May 23, 2019: Ottobock creates considerable value 151

11.5.4 May 14, 2019: AorTech International: Trading update 152

11.5.5 Apr 26, 2019: Sanofi delivers strong Q1 2019 business EPS growth of

9.4% at CER 152

11.5.6 Apr 10, 2019: SANUWAVE provides an update on international registrations received, attendance at Trade Shows and ISO Certification 158

11.5.7 Mar 28, 2019: GSK publishes product sales reporting changes and the impact of IFRS 16 'Leases' 159

11.5.8 Mar 26, 2019: Nexstim publishes prospectus regarding EUR

5.2 million rights issue and new information regarding previous profit forecast 160

11.5.9 Mar 25, 2019: Medtronic launches Medtech Innovation Accelerator in Shanghai 161

11.5.10 Mar 12, 2019: GlaxoSmithKline: Publication of 2018 annual report 162

11.5.11 Mar 11, 2019: New genetic data from Regeneron and GSK on 50,000 UK Biobank participants made available to global health research community 176

11.5.12 Jan 24, 2019: AorTech International: Company Update 177

11.5.13 Jan 23, 2019: Sanofi joins Startup Creasphere – Munich's first digital health focused innovation program 178

11.5.14 Jan 11, 2019: Pre-quarterly results communication 179

11.6 Product News 181

11.6.1 Nov 11, 2019: Simulation-based approach for epilepsy receives regulatory approval 181

11.6.2 Jul 02, 2019: Swiss researchers study personalised neurotechnology stroke therapy 181

11.6.3 May 28, 2019: Brain stimulation may improve sight recovery after stroke 182

11.7 Strategy And Business Planning 182

11.7.1 Oct 15, 2019: Sanofi opens digital manufacturing facility in the US 182

11.7.2 Jun 24, 2019: Boston Scientific Galway expands in to new facility 183

11.7.3 Jun 21, 2019: GSK to raise $1.26bn by selling consumer health brands 184

11.7.4 May 21, 2019: Verily forms strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to transform clinical research 184

12 Appendix 186

12.1 Research Methodology 187

12.1.1 Coverage 187

12.1.2 Secondary Research 187

12.1.3 Primary Research 188

12.1.4 Market Modeling and Forecasting 189

12.1.5 Company Share Analysis 190

12.1.6 Distribution Share Analysis 191

12.1.7 Benchmarking 191

12.2 GlobalData Consulting 192

12.3 Contact Us 192

12.4 Disclaimer 192

Frequently asked questions

EU5 Neuromodulation Devices Outlook to 2025 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EU5 Neuromodulation Devices Outlook to 2025 in real time.

  • Access a live EU5 Neuromodulation Devices Outlook to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.